Register for our free email digests:
Latest From BioMarin Pharmaceutical Inc.
Kala follows July's first biopharma IPO from Ionis spinout Akcea into the stock market. Amicus, Arena and othera go high with major offerings, while Inovio and Regulus go low. Also, Galena, Neothetics provide updates on their hunts for "strategic alternatives."
A legal settlement with BioMarin means that Sarepta doesn't have to worry anymore about the potential to infringe patents related to exon-skipping DMD therapies. Meanwhile, BioMarin gains some compensation for its ill-fated Prosensa buy.
IPOs are up, hemophilia is driving company pipelines, speculation over Pascal Soriot's career plans drive billions from AstraZeneca's market capitalization, Sanofi signs a $650m vaccine deal, private equity bidders up their offer for Stada and earnings season kicks off. Commercial capsule rounds up recent business news and trends reported by sister publication Scrip.
Pipeline Watch: Phase III Starts With Fitusiran In Hemophilia, Zoliflodacin In Gonorrhea, Opdivo Combo In RCC
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Advaxis Inc.
- Senior Management
Daniel J O'Connor, Pres. & CEO
Sara Bonstein, EVP, CFO
Robert Petit, PhD, EVP, CSO
Christopher Duke, SVP, COO
Al Blunt, MD, VP, Medical
Anthony Lombardo, CBO
- Contact Info
Phone: (609) 452-9813
305 College Rd. East
Princeton, NJ 08540
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.